​

Funding Round

Series C - Gracell Biotechnologies

Series C - Gracell Biotechnologies

Investment Firm

Overview

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.

Announced Date

Oct 28, 2020

Funding Type

Series C

Highlights

Location

Asia

Social

Investor Lead

Wellington Management

Wellington Management

Wellington Management is a debt and early_stage_venture and late_stage_venture and private_equity and venture firm.

Participant Investors

5

Investor Name
Participant InvestorOrbiMed
Participant InvestorTemasek Holdings
Participant InvestorLilly Asia Ventures
Participant InvestorWellington Management
Participant InvestorVivo Capital

Round Details and Background

Gracell Biotechnologies raised $100000000 on 2020-10-28 in Series C

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Feb 25, 2019
Series B - Gracell Biotechnologies
5-85.0M
Jan 01, 2018
Series A - Gracell Biotechnologies
1-undefined
Oct 28, 2020
Series C - Gracell Biotechnologies
7-100.0M
Aug 07, 2023
Post-IPO Equity - Gracell Biotechnologies
9-100.0M

Recent Activity

There is no recent news or activity for this profile.